1. Home
  2. AKRO vs NBTB Comparison

AKRO vs NBTB Comparison

Compare AKRO & NBTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • NBTB
  • Stock Information
  • Founded
  • AKRO 2017
  • NBTB 1856
  • Country
  • AKRO United States
  • NBTB United States
  • Employees
  • AKRO N/A
  • NBTB N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • NBTB Major Banks
  • Sector
  • AKRO Health Care
  • NBTB Finance
  • Exchange
  • AKRO Nasdaq
  • NBTB Nasdaq
  • Market Cap
  • AKRO 2.1B
  • NBTB 2.0B
  • IPO Year
  • AKRO 2019
  • NBTB N/A
  • Fundamental
  • Price
  • AKRO $32.33
  • NBTB $44.56
  • Analyst Decision
  • AKRO Strong Buy
  • NBTB Buy
  • Analyst Count
  • AKRO 7
  • NBTB 5
  • Target Price
  • AKRO $43.20
  • NBTB $42.60
  • AVG Volume (30 Days)
  • AKRO 505.3K
  • NBTB 167.7K
  • Earning Date
  • AKRO 11-11-2024
  • NBTB 10-28-2024
  • Dividend Yield
  • AKRO N/A
  • NBTB 3.05%
  • EPS Growth
  • AKRO N/A
  • NBTB 0.14
  • EPS
  • AKRO N/A
  • NBTB 2.85
  • Revenue
  • AKRO N/A
  • NBTB $538,802,000.00
  • Revenue This Year
  • AKRO N/A
  • NBTB N/A
  • Revenue Next Year
  • AKRO N/A
  • NBTB $14.64
  • P/E Ratio
  • AKRO N/A
  • NBTB $15.63
  • Revenue Growth
  • AKRO N/A
  • NBTB 10.23
  • 52 Week Low
  • AKRO $13.39
  • NBTB $32.79
  • 52 Week High
  • AKRO $37.00
  • NBTB $50.84
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 64.31
  • NBTB 48.95
  • Support Level
  • AKRO $30.13
  • NBTB $43.42
  • Resistance Level
  • AKRO $32.70
  • NBTB $46.21
  • Average True Range (ATR)
  • AKRO 1.42
  • NBTB 1.06
  • MACD
  • AKRO 0.11
  • NBTB 0.03
  • Stochastic Oscillator
  • AKRO 86.40
  • NBTB 35.40

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About NBTB NBT Bancorp Inc.

NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. NBT Bank is a full-service community bank offering a full range of retail and commercial banking products and trust and investment services. Loan products include consumer, home equity, mortgage, business banking, and commercial loans. Nearly half of its loan portfolio is in commercial loans. The bank serves individuals, corporations, and municipalities, and operates scores of locations throughout New York, Pennsylvania, Vermont, Massachusetts, New Hampshire, and Maine.

Share on Social Networks: